Back to News
Market Impact: 0.12
Avalyn Pharma Adds Former FDA Executive To Board As AP01, AP02 Trials Progress
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Avalyn Pharma appointed Robert J. Meyer, a pulmonary physician and former senior FDA executive, to its board of directors. The addition may strengthen regulatory and clinical expertise for the clinical-stage biopharmaceutical company, but no financial, trial, or product-development updates were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
AVLN0.30
More News
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- Halozyme prices $1.3 billion convertible notes offering
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- ‘We need sufficient means of control before it is all too late’: King Charles III warns AI players on concerns of ‘existential dangers’
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- AI Software for Buy-Side Teams: Build the Research Stack